Komori
Share Issuance and Disposal4536SANTEN PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding Completion of Payment for the Disposal of Treasury Shares as Post-Delivery Performance-Linked Stock Compensation

Payment for 68,912 treasury shares disposed of as post-delivery performance-linked stock compensation has been completed. The eligible recipients are 3 directors, excluding outside directors, and 7 executive officers.

Worth reading
39Recurring
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
68912
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Disposal of treasury shares as deferred-delivery performance-linked share compensation

Who receives how much68,912Shares

68,912 treasury shares

3 directors (excluding outside directors)35,881 shares
7 executive officers33,031 shares

The height of each bar represents the proportion of shares received by each allottee. The thin line below represents the number of existing shares to which these shares are added.

¥1,867.5 per share
Total issue value

¥128,693,158

Categories and Number of Persons Covered
Category Directors (excluding outside directors) / Number of Employees 3 / Number of allocated shares 35,881 shares, Category Executive officers / Number of Employees 7 / Number of allocated shares 33,031 shares
Payment date
30 September 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalDisposal of treasury shares as deferred-delivery performance-linked share compensation
Number of shares to be issued or disposed of68,912 treasury shares
Issue price and disposal price¥1,867.5 per share
Total issue value¥128,693,158
Payment date30 September 2026
Intended allotteeName 3 directors (excluding outside directors) / Number of Shares 35,881 shares, Name 7 executive officers / Number of Shares 33,031 shares
Categories and Number of Persons CoveredCategory Directors (excluding outside directors) / Number of Employees 3 / Number of allocated shares 35,881 shares, Category Executive officers / Number of Employees 7 / Number of allocated shares 33,031 shares
Items this document does not state (21)
Amount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The payment procedures for the disposal of treasury shares as post-delivery performance-linked stock compensation, as resolved at the Board of Directors meeting held on 3 September 2026, have been completed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Completion of Payment for the Disposal of Treasury Shares as Post-Delivery Performance-Linked Stock Compensation | SANTEN PHARMACEUTICAL CO.,LTD. (4536) timely disclosure | Komori